| 
| 
|  |  | Press Releases |  |  |  |  |  | 
|  |  | Friday, October 31, 2025 |  |  |  
| HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus |  | HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM). more info >> |  |  |  | Wednesday, September 17, 2025 |  |  |  
| EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes |  | HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic diseases, announced that data from the Phase 3 SYMPHONY 2 trial evaluating the safety and efficacy of HTD1801 in patients with type 2 diabetes mellitus (T2DM) is being presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna. more info >> |  |  |  | Thursday, April 24, 2025 |  |  |  
| HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025 |  | HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the EASL Congress 2025, taking place from May 7-10, 2025 in Amsterdam.  more info >> |  |  |  | Tuesday, April 15, 2025 |  |  |  
| Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA |  | HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic liver and metabolic diseases, today announced that two Phase 3 trials (SYMPHONY 1 and SYMPHONY 2) of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints. more info >> |  |  |  | Tuesday, March 4, 2025 |  |  |  
| HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open |  | HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, today announced that data from the Phase 2 proof-of-concept study evaluating berberine ursodeoxycholate (HTD1801) for the treatment of type 2 diabetes mellitus (T2DM) was published online in JAMA Network Open. more info >> |  |  |  | Friday, October 25, 2024 |  |  |  
| HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024 |  | HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, will present at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting, taking place from November 15-19, 2024 in San Diego, California.  more info >> |  |  |  | Wednesday, September 11, 2024 |  |  |  
| EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801) |  | HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, presents at the 60th European Association for the Study of Diabetes (EASD) Annual Meeting, taking place from September 10-13, 2024 in Madrid, Spain.  more info >> |  |  |  | Friday, June 21, 2024 |  |  |  
| HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA  Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801) |  | HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the American Diabetes Association's (ADA) 84th Scientific Sessions, taking place from June 21-24, 2024 in Orlando, Florida. more info >> |  |  |  | Wednesday, June 5, 2024 |  |  |  
| HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801) |  | HighTide Therapeutics, Inc. (HKEX: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy. more info >> |  |  |  | Wednesday, January 11, 2023 |  |  |  
| HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study) |  | HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH"). more info >> |  |  |  |  |  |  |  |  |  |  |  | 
	|  |  | 
 
|  |  
| Latest Press Releases |  |  |  | 
| 
| EESystem Triumphs Again: Courts Deem Jason Shurka's Claims "Baseless" and "Futile" Oct 31, 2025 21:45 HKT/SGT
 |   |  |  |  
| Autumn Lighting Fair, Outdoor and Tech Light Expo, Eco Expo Asia draw some 62,000 buyers Oct 31, 2025 19:56 HKT/SGT
 |   |  |  |  
| Saudi Arabia Assumes Chairmanship of INTOSAI Oct 31, 2025 19:45 HKT/SGT
 |   |  |  |  
| T-RIZE Strategically Collaborates with Republic and Canton to Launch the First New Construction Real Estate Equity Tokenization Deal on Canton Network, phase one of a $200M plan Oct 31, 2025 15:50 HKT/SGT
 |   |  |  |  
| IPO Watch - High-Margin International Business Scales Up Rapidly: Unpacking Hithium Energy Storage's Global Expansion Ambition Behind its Push for a Hong Kong Listing   Oct 31, 2025 15:20 HKT/SGT
 |  |  |  |  
| CIMC Group Announces the First Three Quarter Results for 2025 Oct 31, 2025 14:16 HKT/SGT
 |   |  |  |  
| Hong Kong delegation concludes mission in Riyadh Oct 31, 2025 11:19 HKT/SGT
 |   |  |  |  
| The Executive Centre Unveils New Premium Flexible Workspace at One IFC, Central Hong Kong   Oct 31, 2025 09:19 HKT/SGT
 |   |  |  |  
| Doubleview Gold Corp Announces Non-Brokered Private Placement of Flow-Through Shares at $1.00 per share along with Non-Flow-Through Units Oct 31, 2025 09:09 HKT/SGT
 |   |  |  |  
| HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus Oct 31, 2025 9:30 JST
 |   |  |  |  
| TruMerit's Peter Preziosi Elected President of the Conference of NGOs in Consultative Relationship With the United Nations Oct 31, 2025 04:00 HKT/SGT
 |   |  |  |  
| MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project Oct 30, 2025 23:14 JST
 |   |  |  |  
| NEC and e& Sign MoU to Drive Joint Sustainability Initiatives Oct 30, 2025 22:46 JST
 |   |  |  |  
| MHI Thermal Systems Launches Two New Models of Air-to-Water Heat Pumps Using Natural Refrigerant R290 for European Market Oct 30, 2025 22:19 JST
 |   |  |  |  
| Decent Cybersecurity Highlights Slovakia's Tech Leadership at the EU-NZ Business Summit   Oct 30, 2025 21:00 HKT/SGT
 |   |  |  |  |  |  | More Press release >> |  |  |  |  |  
|  |  
|  |  |  |